cLAG3-IL2 / Bonum Therap - LARVOL DELTA

A novel method for generating regulated cytokine therapeutics: Safety and activity of a conditionally active cLAG3-IL2 capable of delivering IL2 to LAG3+ cells while remaining inert on LAG3- cells (AACR 2024) - "Furthermore, cLAG3-IL2 demonstrates robust combinatorial activity with anti-PD1. These results demonstrate the strength of the Bonum platform, currently applied to multiple target/effector pairs including PD1, PDL1, ATP, LRRC15 and effectors IFNα, IL12 and TGFβ inhibition, and support the clinical development of our conditionally active cLAG3-IL2."

Clinical • IO biomarker • Oncology • CD8 • IFNA1 • IL12A • IL2 • LAG3 • LRRC1 • TGFB1

Bonum Therapeutics to Present Poster on Lead Program at AACR 2024 (Businesswire) - "Bonum Therapeutics...announced the first public presentation of preclinical data on its lead program, a conditionally active LAG3-IL2 therapeutic. Scientists from Bonum will present these data in a poster at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024....The poster presentation will highlight a conditionally active therapeutic called cLAG3-IL2 that targets IL-2 to LAG3+ cells while remaining systemically inert, even at high treatment doses. The in vivo safety and efficacy data described in the poster demonstrate that this program is suitable for progressing into the clinic."

Preclinical • Oncology